Urokinase plasminogen activator receptor-targeted radiopharmaceutical

A targeted radiopharmaceutical that has the chemical Formula I, below,

• wherein Q+3 is a trivalent radioactive isotope ion;
• M is a proton (H+), an ammonium ion or an alkali metal ion;
• “g” is a number whose average value is 1 to about 12 that indicates the average number of chelated PCTA-chelated trivalent radioactive ions per each molecule of mAb MNPR-101 or a paratope-containing portion thereof;
• the boxed mAb MNPR-101 represents a chemically-bonded monoclonal IgG1 kappa light chain subgroup 2 (VK2) type antibody or antigen-binding fragment thereof, whose kappa chain variable region (VL) comprises CDR L1, CDR L2 and CDR L3 that have the respective sequential combination of amino acid residue sequences, respectively, of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5;
• and whose heavy chain variable region (VH) comprises CDR H1, CDR H2 and CDR H3 that have the respective sequential type 1 combination of amino acid residue sequences of SEQ ID NO:
• 10, SEQ ID NO:
• 11 and SEQ ID NO:
• 12;
• and
• Y− is an optional anion present in an amount needed to balance the ionic charge.